Results 171 to 180 of about 3,724 (217)
Targeting AASS improves neurotoxicity and mitochondrial function in astrocyte models for pyridoxine dependent epilepsy [PDF]
Imke M. E. Schuurmans +13 more
openalex +1 more source
Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency [PDF]
et al,, Pearson, Toni S
core +1 more source
ALDH7A1 Gene and Its Related Pyridoxine-Dependent Epilepsy
Flavia Maria Consuelo La Mendola +8 more
openalex +2 more sources
High frequency deep brain stimulation of the hippocampus in a rat model for temporal lobe epilepsy [PDF]
Boon, Paul +9 more
core +1 more source
Lysine <i>α</i>-ketoglutarate reductase as a therapeutic target for saccharopine pathway related diseases. [PDF]
Valderrama GV, Moreira GA, Arruda P.
europepmc +1 more source
Lactic acidosis, rhabdomyolysis, and hyperammonemia: Atypical presentation in a new patient with PDE-ALDH7A1 defect. [PDF]
Bottino M +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Novel mutations in pyridoxine-dependent epilepsy
European Journal of Paediatric Neurology, 2011Pyridoxine-Dependent Epilepsy (PDE) is a rare autosomal recessive disease with neonatal seizures resistant to conventional anti-epileptic drugs. This metabolic disease has to be diagnosed early and treated to improve outcome. We report on two new mutations that open new prenatal prospects and suggest a new diagnostic procedure.We describe PDE in a ...
Millet, Arnaud +7 more
openaire +5 more sources
Gene sleuthing in pyridoxine-dependent epilepsy
Neurology, 2015Epilepsies caused by inborn errors of metabolism consist of a broad range of diseases, typically with early life onset and often associated with progressive encephalopathy. Early recognition and targeted therapy are key to improved outcomes in several metabolic epilepsies, including those related to the pyridoxal vitamer dependencies.
Weckhuysen, Sarah, Pearl, Phillip L.
openaire +3 more sources

